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Background: Drug resistance is a major challenge in cancer therapeutics. Abundant evidence indicates that DNA
repair systems are enhanced after repetitive chemotherapeutic treatments, rendering cancers cells drug-resistant.
Flap endonuclease 1 (FEN1) plays critical roles in DNA replication and repair and in counteracting replication stress,
which is a key mechanism for many chemotherapeutic drugs to kill cancer cells. FEN1 was previously shown to be
upregulated in response to DNA damaging agents. However, it is unclear about the transcription factors that
regulate FEN1 expression in human cancer. More importantly, it is unknown whether up-regulation of FEN1 has an
adverse impact on the prognosis of chemotherapeutic treatments of human cancers.
Methods: To reveal regulation mechanism of FEN1 expression, we search and identify FEN1 transcription factors or
repressors and investigate their function on FEN1 expression by using a combination of biochemical, molecular,
and cellular approaches. Furthermore, to gain insights into the impact of FEN1 levels on the response of human
cancer to therapeutic treatments, we determine FEN1 levels in human breast cancer specimens and correlate them
to the response to treatments and the survivorship of corresponding breast cancer patients.
Results: We observe that FEN1 is significantly up-regulated upon treatment of chemotherapeutic drugs such as
mitomycin C (MMC) and Taxol in breast cancer cells. We identify that the transcription factor/repressor YY1 binds
to the FEN1 promoter and suppresses the expression of FEN1 gene. In response to the drug treatments, YY1 is
dissociated from the FEN1 promoter region leading over-expression of FEN1. Overexpression of YY1 in the cells
results in down-regulation of FEN1 and sensitization of the cancer cells to MMC or taxol. Furthermore, we
observe that the level of FEN1 is inversely correlated with cancer drug and radiation resistance and with
survivorship in breast cancer patients.
Conclusion: Altogether, our current data indicate that YY1 is a transcription repressor of FEN1 regulating FEN1
levels in response to DNA damaging agents. FEN1 is up-regulated in human breast cancer and its levels inversely
correlated with cancer drug and radiation resistance and with survivorship in breast cancer patients.
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Chemotherapy is a major therapeutic treatment for cancer.
The effectiveness of most current chemotherapeutic drugs
for cancer depends on the ability to induce DNA damage
in hyper-proliferating cancer cells, which have inadequate
DNA repair capacity. However, the development of multi-
drug resistance (MDR) in cancer cells poses a major chal-
lenge to chemotherapy and greatly limits the anti-cancer
efficacy of chemotherapeutic drugs [1,2]. Such resistance
arises in cancer cells and cancer stem-like-cells not only
because of the alteration in drug transport and metabolism
that results in low level of anticancer efficacy, but also be-
cause of the increased tolerance for DNA lesion and en-
hanced DNA replication and repair capacity [1-5]. DNA
repair pathways, including base excision repair (BER), nu-
cleotide excision repair (NER), mismatch repair (MMR),
interstrand crosslink repair (ICL), non-homologous end
joining (NHEJ), and homologous recombination (HR),
have been implicated to play important roles in modulating
the response of human cancer to chemotherapy. Previous
studies have shown that cancer cells resistant to chemo-
therapeutic drugs have abnormally high DNA repair cap-
acity [6]. Furthermore, inhibition of DNA repair has
successfully sensitized the cancer cells to cytotoxic killing
by chemotherapeutic drugs [7].
Efficient DNA damage repair partly depends on the
structure-specific nuclease family members, which re-
move damaged bases or nucleotides and process various
DNA intermediate structures. Flag endonuclease 1
(FEN1) is an important member of this family, playing a
pivotal role in DNA replication and repair [8-10]. Al-
though FEN1 was once widely considered a tumor sup-
presser [11] based on its role in the maintenance of
genomic stability through Okazaki fragment maturation,
long-patch base excision repair [12-14], rescue of the
stalled replication fork [15], and telomere maintenance
[16-19], accumulated evidences now indicate that FEN1 is
required for tumor progression [20-23]. Its expression is
up-regulated in response to treatments with anti-cancer
drugs or with radiation admission, thus enhancing DNA
repair pathways and contributing to cancer cells’ survival
under genome toxic stresses [7,22,24]. Using cancer profil-
ing array and immune-histochemistry, we have previously
found that FEN1 is clearly over-expressed in breast cancer
tissues [22]. In addition, FEN1 is also highly expressed in
lung [25] and gastric cancer cell lines [26], as well as pros-
tates cancer [21,27], neuroblastomas [28], testis, lung, and
brain tumors in situ [7]. Interestingly, FEN1 is significantly
up-regulated in mouse fibroblasts in a p53-dependent
manner under genome toxic stresses such as exposure to
UV-C [29] and DNA-alkylating drugs [30]. Recently,
Nikolova et al. showed that down-regulation of FEN1 ex-
pression by siRNA in LN308 glioma cells increased the
cells’ damage-sensitivity to methylating agents such asmethyl methane-sulfonate and temozolomide [7]. All evi-
dences suggest that alteration of FEN1 expression-level
corresponds to cellular responses to chemotherapy or ra-
diation. However, the underlying mechanisms that up-
regulates FEN1 upon drug treatment and confers the drug
resistance to cancer cells remain unclear.
Here, we identify multiple potential transcription fac-
tor binding sites in the FEN1 promoter region. Using
DNA fragments corresponding to FEN1 promoter re-
gions, we pulled down the proteins bounded to the
DNA fragments in the cell crude extracts prepared from
cells grown under normal cell culture conditions and
identified them using mass spectrometry. One of the
outstanding transcription factors that we have identified
is Ying Yang 1(YY1), which plays an important role in
divergent biologic processes such as embryogenesis, dif-
ferentiation, cellular proliferation and cancer progression
[31,32]. YY1 is well known for its dual roles in regulating
gene expression, either as activator or repressor, depend-
ing upon the context in which it binds to [33-36]. In this
study, we found that YY1 is a repressor for FEN1 ex-
pression. In response to DNA damaging agents, YY1 dis-
sociated from FEN1 promoter, leading to up-regulation
of FEN1 for DNA repair. Furthermore, we revealed that
the elevated FEN1 level promotes the efficiency of DNA
repair, which consequently leads to drug resistance and
poor prognostics.
Methods
Design of the biotinylated DNA probes
We predicted the potential transcriptional factors bound to
the −300/+70 fragment of hFEN1’s promoter with the fol-
lowing databases: Match1.0-public, TESS, and TFSEARCH.
We found 200 transcriptional factors including NF-kB,
YY1, p300, USF1, NRF-2 (Figure 1A). We designed the
probes covering the majority of the transcription factor
binding sites. The sequences of all of the probes including
Probe a, Probe b, Probe c, Probe bSNP and Probe R, which
are random sequence controls, are listed in Additional file
1: Table S6. These probes were synthesized by Sangon Bio-
tech (Shanghai, China).
Preparation of nuclear extracts
Crude nuclear extracts from HeLa cell were prepared ac-
cording to a procedure previously described [37]. In brief,
the harvested cells were washed twice with ice cold PBS
and resuspended in 5 package cell-volume of buffer A
(10 mM HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl,
0.5 mM dithiothreitol) containing protease inhibitor cock-
tail (Roche, Indianapolis, IN, USA). NP-40 was added to a
final concentration of 0.5% and kept on ice for 10 min. The
nuclear pellet was obtained by centrifugation at 1500 rpm
for 4 min at 4°C. Then the pellet was washed by 5 package
cell-volume buffer A without NP-40. Supernatant was
Figure 1 Identification of YY1 as a potential transcription regulator for FEN1. A. Top 10 hits of the transcription factors (TFs) that were
predicted by TF Research Web sites: Match1.0-public, PROMO, and TFSEARCH. B. The oligo probes were designed to cover different regions of the
predicted FEN1 promoter. Probes a, b, and c correspond to the region −290 to −230, −150 to −90, and −60 to 0, respectively. C. The silver staining
image of oligo-pulled-down assays using HeLa cell extracts. bSNP: probe b with three SNP sites, r: a probe with random DNA sequences. The unique
band, which is indicated by a box, was subjected to MS analysis. D. Top 10 hits of the MS analysis of the unique protein band as specified in Panel C.
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volume of buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl2,
420 mM NaCl, 0.2 mM EDTA, 2.5% glycerol) with protease
inhibitors. The mixture was sonicated for 5 s and kept on
ice for 60 min. and vertex briefly every 10 mins. The nu-
clear extracts (supernatants) were obtained with centrifuga-
tion for 10 min at 12,000 g and 4°C.
Biotinylated DNA probe pull down assay and mass
spectrometry
Biotinylated DNA pull-down assay was performed as
previously described [37,38] with modifications. 100 μl
(50 nM) of biotinylated probe were incubated with
200 μl HeLa nuclear extracts in 700 μl binding buffer
(25 mM Tris, 150 mM NaCl, pH 7.2) with protease in-
hibitor cocktails and phosphatase inhibitor cocktails
(Roche, Indianapolis, IN, USA) for 30 minutes at room
temperature with gentle rotation. 20 μl streptavidin con-
jugated agarose (Pierce, Rockford, IL, USA) was washed
with PBS (pH 7.4) and was added into the DNA-protein
complexes for 1 hour at room temperature with gentle
rotation. Agarose bead-DNA-protein complexes were
washed three times with ice cold binding buffers and
then were eluted in SDS-PAGE loading buffer by heating
at 95°C. All samples were loaded onto 12% SDS-PAGE,
followed by silver staining with silver stain kit (Beyotime,
China). The unique protein band as shown in Figure 1Cwas excised and subjected to mass spectrometry analysis
(Protein Mass Spectrometry Analysis Center, Institutes
of Biochemistry and Cell Biology, Chinese Academy of
Sciences, Shanghai).
Protein expression and purification
3xFlag tagged YY1 was expressed in 293 T cells and
purified following a published protocol [39]. Briefly,
pCMV7.0-YY1, which encodes the recombinant 3xFlag
tagged YY1, was transfected into 293 T cells. After re-
moval of the transfection reagent, the cells were incu-
bated in fresh DMEM medium for 48 h and then
harvested. The cells were lysed in 1 ml lysis buffer (Tris
50 mM, 500 mM NaCl, 10% Glycerol, 0.5% NP40, 1 mM
DTT, 1 mM EDTA, 1 mM PMSF and protease inhibitor
cocktail), and the lysates were centrifuged at 20,000 g
for 10 min. The supernatant was incubated with equili-
brated 25 μl Anti-Flag M2 magnetic beads (Sigma, St
Louis, MO, USA) for 12 h. After it was extensively
washed with lysis buffer, the 3xFlag tagged YY1 was
eluted with 50 μl 2 mg/ml 3xFlag peptide (Genescript,
China). The primers used to amplify the YY1 cDNA are
listed in Additional file 1: Table S6.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed as described previously [40] by using
the Light Shift chemiluminescent EMSA kit (Thermo
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binant YY1 protein and the biotin-labeled double strand
DNA. These probes, which represent the FEN1 promoter
regions, include negative control Probe N, positive control
Probe P, WT FEN1 and MUT FEN1. The positive control
probe (Probe P) is the same Probe as the Probe b used in
the biotinylated DNA pull-down assay. The MUT FEN1
probe contains two mutated nucleotide residues indicated
with low case. These probes are listed in Additional file 1:
Table S6.
Chromatin immunoprecipitation (ChIP)
ChIP assay was performed as described previously [40].
The rabbit anti-YY1 antibody was purchased from Santa
Cruz Biotechnology (Santa Cruz Biotechnology, Dallas, TX,
USA). The protein A/G agarose beads were purchased from
Pierce (Pierce, Rockford, IL, USA) and mouse IgG conju-
gated with magnetic beads were purchased from Cell Sig-
naling Technology (Cell Signaling Technology, Danvers,
MA, USA) as the negative control. Besides the control IgG,
the amount of ACTB and FEN1 CDS DNA fragment that
was precipitated and analyzed under same conditions
served as an additional control for specificity of the binding
between the ChIP antibodies and their target genes. ChIP
primers for the FEN1 promoter, FEN1CDS and ACTB, as a
control, are listed in Additional file 1: Table S6.
Cell culture, transfection, treatment, and flow cytometry
The 293 T, HeLa, MCF-7, MDA-MB-231 cells were ob-
tained from ATCC. Cells were cultured in DMEM
(Hyclone, Logan, UT, USA) supplemented with 10% fetal
bovine serum (Pufei, China). 1 × 106 MDA-MB-231 or
MCF7 cells were seeded in 6 well-plate for 24 h at 37°C, 5%
CO2, then treated with 5 μM Mytomycine C (MMC)
(Sigma, St Louis, MO, USA) for 1 h. After treatment, cells
were collected 9 and 16 hours later for RT-PCR and
Western blotting to detect the YY1 and FEN1 protein
and mRNA levels, respectively. In parallel, cells were
treated with Taxol (Melone, China) in a concentration
of 20 nM for 24 h and were then collected for RT-PCR
and Western blotting.
The transfections were carried out according to standard
procedures using SuperFectin II DNATransfection Reagent
(Pufei, China) and the EGFP intensity was measured
with the Cytomics TM FC 500 Flow Cytometer System
(Beckman Coulter, Pasadena, CA). To detect the effects
of the YY1 level in cellular response to the drugs, 239 T
cells were transfected with pcDNA3.1-YY1. The cell
survival fractions at different time points were mea-
sured by cell counting.
Western blotting
Western blotting analysis was performed according to
standard procedures using ECL detection substrate (Pierce,Rockford, IL, USA) and the blot was exposed to the Tannon
5200 System for visualization. The antibodies used in our
studies were the rabbit polyclonal anti-YY1 antibody (Santa
Cruz), the rabbit monoclonal anti-FEN1 antibody (Novus
Biologicals, Littleton, CO, USA), the Horseradish peroxid-
ase (HRP)-conjugated anti-GAPDH (GenScript, China),
and the Horseradish peroxidase (HRP)-conjugated anti-
rabbit secondary antibody (Pierce, Rockford, IL, USA).
RT-PCR analysis
Total mRNA was isolated using TRIzol reagent (Life
Technologies, Carlsbad, CA, USA). Reverse transcription
reaction was performed using PrimeScript RT reagent
kit (TaKaRa, Japan) according to the manufacturer’s in-
structions. qRT-PCR was performed in a MJ Chromo 4
(Bio-Rad) by using a reaction mixture with Platinum
SYBR qPCR SuperMix-UDG (Invitrogen, Carlsbad, CA,
USA). All the PCR amplification was performed in tripli-
cate and repeated in three independent experiments.
The sequence for all of the primers for human FEN1,
human YY1, and the internal control of human GAPDH
and EGFP are listed in Additional file 1: Table S6.
Disease free survival analyses based on the data available
in the literature
FEN1 survival analyses were determined based on
Ivshina et al. [41]. In their study, the gene expression
was profiled with 347 primary invasive breast tumors
using Affymetrix microarray. Data were deposited to
Gene Expression Omnibus (GEO) database (GSE4922).
The FEN1 expression ‘high’ and ‘low’ groups were segre-
gated based on median expression values. Kaplan-Meier
survival analysis was used to determine the survival differ-
ences between ‘high’ and ‘low’ expression, visualized by
Kaplan-Meier plots and compared using Cox regression
analysis, with p-values calculated by log-rank test using the
Survival package in R [42]. Survival analyses were per-
formed on all patients, including ER+ subgroups, ER- sub-
groups and ER negative and lymph node negative (ER-LN-)
groups respectively for clinical interest.
Patient information and tumor specimens for prognostic
outcome analysis
The use of specimens from human subjects was approved
by the Ethics Committee of China Medical University
(CMU). A total of 288 primary breast cancer patients from
the archives of the Department of Pathology in the First
Hospital of CMU were initially recruited in the current
retrospective study. All patients included in the study
were the ones who had surgery between May 1995 and
December 2009. Patients were selected into the study
based on the availability of complete clinical medical re-
cords, follow-up data and an adequate number of
paraffin-embedded tissue blocks.
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of Oct. 2013. The medium follow-up duration was
90.8 months with a range from 11.7 to 167.4 months.
The overall survival (OS) was set on the period from the
date of surgery to death or to the most recent clinic visit.
The disease-free survival (DFS) was set on the period
from the date of surgery to recurrence, death, or to the
most recent clinic visit. The complete demographic and
clinical data were collected retrospectively. Formalin-
fixed, paraffin-embedded tumor specimens were ob-
tained from the archives of the Department of Pathology
of the First Hospital of CMU and three pathologists ex-
amined all the specimens to confirm histopathological
features. The tumors were staged according to the cri-
teria set by the American Joint Committee on Cancer
(AJCC) stage (The 7th edition).
Tissue microarray and IHC
A tissue microarray was constructed in collaboration
with Shanghai Biochip (Shanghai, China). Two punch
cores of 1.0 mm were taken from each patient sample
from the non-necrotic area of tumor foci. IHC protocols
are described in detail [22]. After they were counterstained
with Meyer’s haematoxylin, the sections were observed
under a light microscope by an experienced pathologist
with cytoplasmical or nuclear patches of brown scored as
FEN1-positive. For YY1, a cell was considered positive if
there were brown patches in nuclei. A scale was applied to
quantify the extent of expression: 0 = no detectable or only
trace staining, 1 = weak expression, 2 = strong expression.
Score 0 was considered as “low expression”, and score 1
and 2 were considered as “high expression”.Prognostic outcome analysis
A Spearman’s correlation test was used to assess rela-
tionships between variables. Survival curves were plotted
by the Kaplan-Meier (KM) method and compared with
the log-rank test. All the clinicopathological variables
listed in Additional file 1: Table S1 were included in a
multivariate Cox model that was modified in a backward
stepwise manner to select the variables that carried
prognostic value independent of each other. The associa-
tions with FEN1, YY1 or combination of the two and
clinical outcomes were assessed using an unadjusted
model and after adjusting for the selected variables in the
previous step. Hazard ratios (HR) and 95% confidence in-
tervals (CI) were estimated. The cutoff values were se-
lected on quartiles, and the frequency of distribution of
variables, the size, and the number of events in each sub-
group were also considered. Groups with similar survival
were merged. All statistical tests were two-tailed with a
P < 0.05 considered significant. SPSS statistical software
(SPSS, Inc.) was used for the above statistical analysis.Results
Identification and validation of transcription factor YY1
binding to FEN1 promoter
We previously showed that the −458 to +278 region of
the FEN1 gene promoter is essential to drive its expres-
sion [22]. To investigate which transcription factors
regulate FEN1 expression, we first employed bioinfor-
matics studies using the Match 1.0-public, TESS, and
TESEARCH databases to predict the potential tran-
scriptional factor binding sites in the region from −300
to +70 nt of hFEN1’s promoter. These analyses revealed
the consensus binding elements for nearly 200 tran-
scription factors including NF-kB and YY-1 (Figure 1A).
To experimentally determine whether these transcrip-
tion factors indeed bind to the FEN1 promoter, we de-
signed three probes (a, b, and c) to cover different
regions of the human FEN1 promoter (Figure 1B). The
probes a, b, and c correspond to the promoter regions
from −290 to −230, −150 to −90, and −60 to 0, respect-
ively. In addition, probe bSNP contains the same region
of −150 to −90 as probe b, but includes three single nu-
cleotide polymorphisms that have been reported in
NCBI database. Using these probes, we pulled down the
proteins bounded to the DNA fragments in the cell
crude extracts prepared from HeLa cells grown under
normal cell culture conditions. On the silver stained
SDS-PAGE, we observed a unique band (boxed) in the
lanes of the probe b pulled-down proteins (Figure 1C).
The band was also present in the lane of the probe bSNP
pulled-down proteins, indicating SNPs do not influence
the binding capacity of the contained transcriptional
factors. To reveal what proteins correspond to this
band, we excised the band and identified the proteins
with mass spectrometry analyses. Transcriptional factor
YY1 was among the top 10 hits (Figure 1D).
YY1 is a ubiquitously distributed transcriptional factor
that regulates numerous gene expressions [43-47]. We
found that the binding site for YY1 on FEN1 promoter
was conserved based on the sequence alignment of the
predicted YY1 binding motif to the binding sites from
various genes (Figure 2A). To validate whether YY1 in-
deed binds to the predicted YY1 binding site on the
FEN1 promoter region, we performed the electrophor-
etic mobility shift assay (EMSA) using the purified re-
combinant YY1 protein and the DNA probe, a 29 base
pair oligonucleotide covering the predicted YY1 binding
site. We found that YY1 effectively binds to the wild
type probe, forming the YY1/DNA complex, which dis-
played a retarded migration compared to the free probe.
Furthermore, substitution of the conserved “C” and “T”
nucleotide with “G” and “A” abolished the formation of
the YY1/DNA complex (Figure 2B). To further verify the
binding of YY1 to the DNA sequence in the FEN1 pro-
moter region, we added non-specific IgG or anti-YY1
Figure 2 YY1 binds to the conserved YY1 binding motif in the FEN1 promoter region. A. Sequence alignment of the conserved YY1
binding motif in different proteins. B. EMSA analysis of YY1 binding to the YY1 binding motif in the FEN1 promoter. Recombinant YY1 was
incubated with different biotin-labeled DNA probes. The sequences of the Probe N, Probe P, WT FEN1and MUT FEN1 can be found in Additional
file 1: Table S6. The free probe and YY1/DNA complex were resolved in 5% native PAGE. C. EMSA assay on YY1 and FEN1 oligo in the presence of
non-specific IgG or the anti-YY1 antibody. D. ChIP analysis of YY1 binding to the FEN1 promoter region. Specific YY1-bound DNA in MCF7 cell
extracts was pulled down by an anti-YY1 antibody. The YY1-bound FEN1 sequence was amplified by PCR. The sequence for the FEN1 promoter
specific primer can be found in the Additional file 1: Table S6 as FEN1 (YY1). The PCR product was analyzed by 1% agarose electrophoresis.
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sequence. Addition of anti-YY1 but not non-specific IgG di-
minished the YY1-oligo complex (Figure 2C), suggesting
that YY1 specifically bound to the oligo sequence of FEN1
promoter. We then investigated whether YY1 bound to the
FEN1 promoter region in MCF7 breast cancer cells by con-
ducting a chromatin immune-precipitation-PCR (ChIP-
PCR) and showed that the FEN1 promoter was specifically
pulled-down by an YY1-specific antibody but not the con-
trol antibody (Figure 2D). The results all suggest that tran-
scriptional factor YY1 binds to the FEN1 promoter.
Anti-cancer drugs release the YY1 suppression to FEN1
leading to its over-expression and drug resistance
YY1 is a multifunctional protein and can work as either
a gene expression repressor or an activator [35,48]. To
determine the roles of YY1 in regulation of FEN1 ex-
pression, we exogenously overexpressed YY1 in 293 T
cells and evaluated the FEN1 protein level. We found
that the protein level of endogenous FEN1 gradually de-
creased as the amounts of the plasmid DNA transfectedinto 293 T cells increased (Figure 3A). We next exam-
ined whether YY1 bound to the FEN1 promoter region
and suppressed the gene expression. We sub-cloned the
FEN1 promoter into the pGL4.0 plasmid, so that the ex-
pression of the EGFP reporter gene was only driven by the
FEN1 promoter. The Flag-tagged YY1 expression vector
and the pGL4.0-FEN1 promoter-driven EGFP vector were
co-transfected into 293 T cells. The overexpression of
Flag-tagged YY1 was confirmed by PCR and western blot
(Figure 3B and C). We then measured the EGFP mRNA
level by qPCR and the EGFP protein by flow cytometry.
Our data indicated that the ectopic over-expression of
YY1 in 293 T cells considerably reduced EGFP mRNA and
protein levels (Figure 3B, D and E). Next, we determined if
a decrease in YY1 level resulted in up-regulation of FEN1
expression. We knocked down YY1 in 293 T or MCF7
cells by shRNA specific against YY1 sequences. We found
that knockdown of YY1 was associated with significant in-
crease in FEN1 expression level in both 293 T and MCF7
cells (Figure 3F). Similar phenomenon was observed in
HeLa and U251 cancer cells.
Figure 3 (See legend on next page.)
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Figure 3 Overexpression of YY1 inhibits FEN1 promoter-driven protein expression. A. YY1 was overexpressed in 293 T cells and its impact
on the FEN1 protein level was evaluated by western blot using the anti-Flag or anti-FEN1 antibody. B. The pCMV-Flag-YY1 expression vector and the
pGL4.0-FEN1 promoter-EGFP vector, or pGL4.0 EGFP vector was co-transfected into 293 T cells. The EGFP expression was detected by semi-quantitative
PCR (Upper panel) and quantitative PCR (lower panel). C. The overexpression of Flag-tagged YY1 was confirmed by western blot using the anti-Flag
antibody. D and E. EGFP protein levels with or without YY1 overexpression was measured by FACS. Panel D shows the representative FACS images.
Panel E is the quantification of FACS. Values are means ± s.d. of four independent experiments. p value was calculated by the two-tail student’s t-test.
F. Knockdown of YY1 in 293 T (Left Panel) and MCF7 (right panel) cells. The YY1 and FEN1 expression was measured by quantitative PCR. The mRNA
level was normalized with corresponding mRNA level of GADPH, and the normalized mRNA level of YY1 or FEN1 in the cells treated with control siRNA
was arbitrarily set as 1. Values are means ± s.d. of three independent experiments. p value was calculated by the two-tail student’s t-test.
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chemotherapeutic drugs relieve such a restraint, leading
to induction of FEN1 expression. We treated the breast
cancer cell line MDA-MB-231 with mitomycin C
(MMC) and Taxol and performed qPCR and Western
blotting to analyze the gene expression of YY1 and
FEN1. We found that in response to treatments with
MMC and Taxol, the mRNA level of YY1 was down-
regulated by more than 2 folds, while the mRNA level of
FEN1 was up-regulated by 3 to 6 folds (Figure 4A and
B). We consistently observed that the YY1 protein level
was reduced by approximate 2 folds, while the protein
level of FEN1 increased by more than 2 folds. In
addition, we tested whether the drug treatment also im-
pairs the binding of the transcription factor to the FEN1
promoter. Indeed, our ChIP analyses indicated that the
amount of YY1 bound to the FEN1 promoter reduced by
2 folds upon the MMC treatment (Figure 4C). Further-
more, when we overexpressed the Flag-tagged YY1 in
293 T cells (Figure 4D), we observed that the cells harbor-
ing this expression plasmid became more sensitive to both
MMC and Taxol treatment (Figure 4E and F).
To support the notion that different DNA damage
agents and therapeutic drugs induce FEN1 gene expres-
sion, we employed an expression array of 26 cancer cell
lines in 13 major categories that have been treated with
25 different DNA-damaging agents and therapeutic drugs
(Figure 5A). The fact that FEN1 expression was high in
breast cancer cell lines was consistent with our published
data [22]. The Northern dot blotting results showed that
FEN1 expression levels in breast cancer cell lines, MDA-
MB-4355 and MDA-MB-231, increased significantly (by
more than 8 folds) after the treatment with DNA-damaging
agents, such as camptothecin, cytochalasin D, MMC, and
gamma irradiation (Figure 5A and B). However, other
agents such as Etoposide, 5-fluorouracil, Aphidicoline and
Taxol, induced the FEN1 expression in MDA-MB-231, but
not in MDA-MB-4355 (Figure 5A and B).
Breast cancer patients with low expression of YY1 and
high expression of FEN1 have poor prognostics
Seeking the relevance between FEN1 expression and
cancer patient outcomes, we performed survival analysisusing 5 different breast cancer patient cohorts, namely
Ivshina [41], Huang [49], Pawitan [50], Sotiriou [51], and
Wang [52], all of which are available in the literature. For
the data from the Ivshina [41], patients were grouped into
High-Risk and Low-Risk subgroups based on 2-mean cat-
egorical clustering of selected significant genes for Kaplan-
Meier survival analysis [41] with high and low expression
levels of FEN1 gene to measure the number of patients liv-
ing for a certain amount of time after the treatment.
Kaplan-Meier analyses revealed that the under-expression
of FEN1 measured by the mRNA level was correlated with
better disease free survival (DFS) outcome. For overall 249
breast tumor samples (p = 0.0007), 211 of ER+ subgroups
(p = 0.005), 34 of ER- subgroups (p = 0.03), 20 of ER-LN-
subgroups (p = 0.007) all showed an inverse correlation of
FEN1 gene expression with DFS (Figure 6A). The inverse
correlation was also validated with other 4 large breast
cancer cohorts (Huang et al. (n = 89; p = 0.004) [49], Pawitan
et al. (n = 159; p = 5.21e-5) [50], Sotiriou et al. (n = 117 p =
0.04) [51] and Wang et al. (n = 286 p = 0.02) [52]. Interest-
ingly, our additional patient cohort data mining indicated
that the difference of the survivorship between the patients
with the low expression and high expression of FEN1 in ER-
and ER-/lymph node negative patient cohorts is much larger
than that in ER+ patients (Data not shown).
Further seeking the association between FEN1 and YY1
expression levels and survivorship in breast cancer pa-
tients, we studied a cohort that made available in the First
Hospital of China Medical University. The characteristics
of the studied cohort are summarized in Additional file 1:
Table S1. After excluding cases with insufficient tumor tis-
sue in tissue micro-array, FEN1 expression was detectable
in 268 cases, and YY1 expression was detectable in 285
cases. The expression of FEN1 was detected in 209 cases
out of a total of 268 cases (78.0%) by IHC staining, while
YY1 was present in 67 cases out of a total of 285 cases
(23.5%) by IHC staining. The association between FEN1
and YY1 expressions with clinicopathological variables of
the cohort is shown in Additional file 1: Table S1. No sig-
nificant association between FEN1 expression and age, T
stage, N stage, stage, ER, PR, HR, Her-2, triple-negative,
being ductal carcinoma in situ (Dcis), using taxane in ad-
juvant therapy, or using standard therapy was found.
Figure 4 DNA damaging agents MMC and Taxol inhibit YY1 expression but induce FEN1 expression. A. and B. YY1 and FEN1 expression
in MDA-MB-231 breast cancer cell line in response to the MMC and Taxol treatment. The mRNA level (A) and protein level (B) were measured by
quantitative PCR and Western blot. The left panel in B showed the quantification of Western blot results. All experiments were independent
carried out at least three times. C. Analysis of YY1 binding to the FEN1 promoter in response to the MMC treatment. Cells were treated with MMC, and
the level of YY1-bound FEN1 promoter was evaluated by the ChIP assay. The lowest DNA staining density is arbitrarily set as 1. D. western blot
confirmed the overexpression of Flag-tagged YY1 in 293 T cells. The β-actin(ACTB) was used as control. E. and F. The survivorship of 293 T cell and
293 T cell harboring a YY1 expression plasmid, pCMV-Flag-YY1, or the empty vector, under treatment of mytomycine C (MMC) (Panel E) or taxol (Panel F).
In both panels, the cells were treated with indicated concentrations of MMC or taxol for 48 hours. The number of survival cells was counted. The survival
rate of the untreated cells with or without YY1 overexpression was arbitrarily set as 1.
Wang et al. BMC Cancer  (2015) 15:50 Page 9 of 15However, high YY1 staining correlated significantly with
ER-positive cases (P = 0.007), PR cases (P = 0.000), HR-
positive cases (P = 0.000), NOT-tri-negative cases (P =
0.030). The correlation between FEN1 and YY1 expression
was not significant.
The 5-year overall survival rate of the cohort was 86.0%.
In a Kaplan–Meier (KM) analysis, FEN1 and YY1 expres-
sions showed no prognostic significance in OS in this co-
hort (P = 0.135 and 0.258, respectively). In contrast,
patients with FEN1-high/YY1-low expression had signifi-
cantly poor overall postoperative survival, compared with
those with other phenotypes (P = 0.027) (Figure 6B). Stagewas the only independent clinicopathological variable to
predict OS (Additional file 1: Table S2.). After adjusting
with the stage, FEN1-high/YY1-low expression could still
predict a poor OS in the multivariate Cox model (P =
0.020, Additional file 1: Table S3). However, in the ER-
negative or ER-negative/lymph-node-metastasis-negative
subgroups, there was no significant association between
the FEN1 expression level, YY1 expression level, or their
combination and OS in the CMU cohort. The similar
trends were observed in association between FEN1 expres-
sion, YY1 expression, their combination, and DFS when
analyzed with KM methods. The corresponding log-
Figure 5 (See legend on next page.)
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Figure 5 FEN1 gene expression in response to chemotherapeutic drug and DNA damage agent treatments. A. Macro-image of
hybridization of the 32-P-labeled FEN1 ORF DNA fragment with the expression array, which contains cDNA from different cells lines treated with
different DNA-damaging agents. In the control hybridization, 32-P-labeled ubiquitin ORF DNA fragment was used [38]. B. The relative fold changes
of the density of the hybridized spots. All FEN1 hybridization signals were normalized with corresponding ubiquitin signals. In each cell line, the
normalized signal in the untreated control sample was arbitrarily set as 1, and the fold change was calculated by comparing the normalized signal
in a specific sample to that of the untreated control sample.
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Patients with FEN1-high/YY1-low expression had signifi-
cantly poor disease free postoperative survival (Figure 6C).
Stage and Her2 status were independent clinicopathological
variables to predict DFS (Additional file 1: Table S4). After
adjusting with these 2 variables, FEN1-high/YY1-low ex-
pression could still predict a poor DFS in the multivariate
Cox model (P = 0.007, Additional file 1: Table S5). However,
in the ER-negative or ER-negative/lymph-node-metastasis-
negative subgroup, there was no significant association
among FEN1, YY1, or combination of the two and DFS.
Discussion
Many chemotherapeutic drugs and ionized radiation
have been employed to kill hyper-proliferating cancer
cells, causing extensive DNA damage in the target cells.
The DNA damage ultimately leads to cell cycle arrest
and cell death. However, the efficacy of these therapeutic
agents such as platinum drugs [53] and alkylating agents
[54] can be significantly reduced by the ability of cells to
repair their DNA. DNA repair involves an intricate net-
work of repair systems that each targets a specific subset
of lesions, including excision repair that replaces dam-
aged or mismatched bases using the complementary
strand as a template and homologous recombination
and non-homologous end joining, both of which repair
double strand breaks. An inverse correlation of ERCC1
(one of the nucleotide excision repair pathway compo-
nents) with response either to platinum therapy or to
survival was clearly established in ovarian cancer [55,56],
non-small cell lung cancer [57] and colorectal cancers
[58]. Moreover, mismatch repair (MMR) deficiency is as-
sociated with cisplatin resistance [59,60]. The MMR
mechanism removes the newly inserted intact base in-
stead of damaged base, triggering subsequent rounds of
futile repairs, which can lead to cell death [61]. Further-
more, a role in triggering checkpoint signaling and apop-
tosis was also suggested [62]. Resistance to alkylating
agents via direct DNA repair by O(6)-methylguanine
methyltransferase (MGMT) has been extensively studied
and is considered to be a significant barrier to the suc-
cessful treatment of patients with malignant glioma [63].
In this study, we have presented data to support such a
notion that FEN1 over-expression has an inverse correl-
ation with survivorship of breast cancer patients andmay serve as a prognostic biomarker. In molecular level,
FEN1 expression is restricted by FEN1 binding with
transcription factor YY1. Upon treatment with cancer
drugs, YY1 is released from the FEN1 promoter so that the
expression of FEN1 is highly induced in cancer cells, conse-
quently leading to drug resistance. Therefore, the patients
with low expression of YY1 and high expression of FEN1
have statistically significantly poor prognostic outcomes. It
is worthy to note that DNA damage-induced FEN1 expres-
sion is at least partly mediated by the transcription factor
p53 [29]. That FEN1 expression is repressed by YY1 is con-
sistent with a previous study indicating that YY1 negatively
regulate of p53 signaling [64].
Involved in DNA replication, DNA repair and apop-
totic DNA fragmentation, FEN1 is a multi-functional
nuclease, and the FEN1 level in human cells is tightly
controlled. Previously, we have shown that FEN1 expres-
sion is controlled by DNA methylation at its promoter
region [22]. In normal breast cells, the promoter region
of FEN1 is hypermethylated and the FEN1 level is low.
However, during neoplastic transformation, this regulation
mechanism is abolished, leading to FEN1 overexpression
in breast cancer cells [22]. More recently, we have further
demonstrated that the FEN1 protein level is also tightly
controlled by sequential phosphorylation, SUMOylation,
and ubiquitination in a cell cycle-dependent manner. Fail-
ure of these regulation processes may result in high FEN1
protein level, which is associated with abnormal cell cycle
progression and genome instability [65]. Here, we reveal a
new regulatory mechanism of FEN1. We demonstrate that
FEN1 gene expression is under control via binding of the
transcription factor YY1 in the normal cell culture condi-
tions. Relative large amount of the YY1 protein can be
pulled down by the FEN1 promoter DNA fragment con-
taining the predicted YY1 binding motif that is conserved
among various gene promoters. Three SNPs available in
the database (NCBI SNP database http://www.ncbi.nlm.
nih.gov/snp/?term=FEN1) beyond the conserved motif did
not affect YY1 binding, while the nucleotide residue re-
placement in the conserved YY1 binding motif completely
erased such a binding. We show that therapeutic drugs are
able to disrupt the YY1 gene expression and YY1 protein
binding to FEN1 promoter region. It is known that YY1 is
constitutively expressed in different types of cells, but its






























































Figure 6 Associations between FEN1, YY1 protein, or their
combination and OS or DFS. A. FEN1 Kaplan Meier survival plot
with breast cancer patient cohort in the Ivshina data base. The black
line indicates FEN1 high expression while the red line indicates FEN1
low expression (‘high’ and ‘low’ determined by median expression).
Patients with FEN1 high expression: 132; patients with FEN1 low
expression: 117, Log-rank p = 0.0007. B. Low expression of YY1 and
high expression of FEN1 and OS in the CMU cohort. The black line
indicates YY1 low but FEN1 high expression and red line indicates
other types. Patients with YY1 low but FEN1 high expression: 154;
patients with other types: 113, Log-rank p = 0.027. C. Low expression of
YY1 and high expression of FEN1 and DFS in the CMU cohort. The
black line indicates YY1 low but FEN1 high expression and red line
indicates other types. Patients with YY1 low but FEN1 high expression:
154; patients with other type: 113, Log-rank p = 0.048.
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sible that therapeutic drugs such as MMC and taxol in-
duced cell cycle arrest and contribute to down-regulation
of YY1. In addition, the drug treatment may induce
changes in post-translational modifications and conform-
ation of YY1 proteins or altering the FEN1 promoter
methylation status, so that the interaction between YY1
and FEN1 promoter is impaired. As a result, the suppres-
sion of FEN1 expression by YY1 is eliminated, and FEN1 is
over-expressed. Consequently, cancer cells become more
resistant to drugs due to enhanced DNA repair systems as
a result of FEN1 over-expression. Moreover, after we artifi-
cially over-expressed YY1 protein, the cancer cells became
more sensitive to drugs. Transcriptional factor binding se-
quence analysis of this region, using the computer pro-
grams TRANSFAC, Match1.0-public, TESS, and
TFSEARCH, suggested that nearly 200 transcription factors
including NF-κB and YY-1 might bind to the FEN1 pro-
moter region. Therefore, what we have seen with YY1
might be only tips of the iceberg. It is crucial to elucidate
the comprehensive network that controls FEN1 gene ex-
pression under both normal and treatment conditions and
to obtain a dynamic picture on how such a control mech-
anism changes in response to different drug treatments.
From the clinical standpoint, FEN1 is a good candidate
biomarker for prognostics of breast cancer patients based
on evidences that we made available in the current studies.
From the data made available by Ivshina [41], we see a
clear distinction between the disease-free survivorship of
the patients with high expression of FEN1 and that of pa-
tients with low expression of FEN1. Namely, more than
80% of patients with low expression of FEN1 can survive,
disease-free, for more than 10 years; however, only less
than 55% of patients with high expression can do so. That
means 25% more patients in the cohort would live for at
least 10 years longer if FEN1 expression were suppressed.
The separation was very much further improved in ER-
(45%) or ER- and lymph node negative patient cohorts
(55%) though the cohort sizes are relatively small in the
Wang et al. BMC Cancer  (2015) 15:50 Page 13 of 15later two cases as only about 10% of breast cancer patients
are ER-. In the patients with not only ER- but also low ex-
pression of FEN1 gene, more than 90% of them would be
able to live for at least 10 years longer. Thus, examining
the FEN1 expression level is very critical to the patients
with ER-. With the patient cohort from the First Hospital
of China Medical University, FEN1 and YY1 expressions
were evaluated with IHC. In that cohort, patients with
FEN1-high and YY1-low expression had both statistically
significantly poor overall and disease-free postoperative
survivals, a fact suggesting that FEN1 and YY1 might have
inverse impact on the survival of breast cancer patients.
This is consistent with the results that we have obtained
from molecular studies using cultured cell lines and clin-
ical drugs. Overall, the FEN1/YY1 interaction and regula-
tory mechanism might be of clinical importance and
should be further investigated.
Conclusion
Altogether, we demonstrate that YY1 plays a critical role in
regulating FEN1 gene expression as a repressor. Reduction
of YY1 levels in breast cancer cells results in overexpression
of FEN1 leading to resistance to chemotherapeutic drugs.
Conversely, overexpression of YY1 in the cancer cells sup-
presses FEN1 expression and sensitizes cancer cells to
DNA damaging drugs. These finding provide basis for tar-
geting YY1 and FEN1 for developing chemotherapy and ra-
diation sensitizers.
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